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Objective. To study the outcome of children with acute lymphoblastic leukae-
mia who were treated using a protocol including one or two delayed
intensifications.
Design. Prospective single-arm multicentre study.
Setting. Five designated children cancer units of the Hospital Authority of Hong
Kong.
Patients. Children aged between 1 and 17.9 years with newly diagnosed acute
lymphoblastic leukaemia seen from November 1997 to December 2002.
Intervention. Chemotherapy was modified from a German Berlin-Frankfurt-
Muenster 95 (BFM95) protocol that included a delayed intensification similar to
the induction phase repeated 5 months after diagnosis. High-risk patients were
given double delayed intensification.
Main outcome measures. Overall survival and event-free survival of the whole
group and the three risk groups (standard-, intermediate-, and high-risk groups),
and comparison with historical controls.
Results. A total of 171 patients were recruited with a median age at diagnosis of
5.57 years (range, 1.15-17.85 years). The induction remission rate was 95.3%
and non-leukaemia mortality during remission was 2.3%. At 4 years, the relapse
rate of this (HKALL97) study was significantly lower than that of the HKALL93
study (15.7 vs 37.3%; P<0.001). The 4-year overall survival of HKALL97 and
HKALL93 studies were 86.5% and 81.8%, respectively (P=0.51). The 4-year
event-free survival for HKALL 97 and HKALL93 studies were 79% and 65%,
respectively (P=0.007). Nonetheless the difference of event-free survival was
most remarkable in the intermediate-risk group: 75.6% and 53.1% for HKALL97
and HKALL93 studies, respectively (P=0.06).
Conclusion. A more intensive delayed consolidation phase improved the out-
come for children with acute lymphoblastic leukaemia by reducing relapses at 4
years. The early treatment complications were manageable and non-leukaemia
mortality during remission remained low.
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Introduction
Acute lymphoblastic leukaemia (ALL) is the most com-
mon childhood malignancy.1 It is highly responsive to
chemotherapy and induction remission rates in most
clinical studies are over 95%.2-4 The major cause of treatment
failure is relapse, mainly in the bone marrow and less
commonly in extramedullary sites such as the central
nervous system (CNS) or testes. With good supportive care,
treatment-related mortality can be kept below 5%. The
challenge of improving treatment outcome is to maintain
continuous remission and prevent relapse. Relapses may
occur in the first 2 to 3 years during chemotherapy, but are
more common 1 to 2 years after stopping chemotherapy.
The current trend of treatment is to increase treatment
intensity in the first 6 to 9 months and continue with a
milder maintenance phase for up to 2 or 3 years after
diagnosis. The mode of intensification in the first 9 months
of treatment nonetheless varies among collaborative
groups. The HKALL93 study5 recruited patients from 1993
to 1997 and adopted the United Kingdom ALL XI study
approach (UKALL XI6). There was a high relapse rate in
intermediate- and high-risk patients.5 The Hong Kong
Paediatric Haematology and Oncology Study Group
commenced a new clinical study in 1997 that adopted a
German Berlin-Frankfurt-Muenster 95 (BFM95) protocol
aimed at improving treatment outcome. The main difference
between the German and UK protocols is the inclusion of
a delayed intensification similar to induction, called
re-induction, 5 months after diagnosis. This study aimed to
determine the outcome of children with ALL who received
a treatment protocol that included either one or two
delayed intensifications.
Patients and methods
From November 1997 to December 2002, all children
newly diagnosed with ALL in the five paediatric oncology
centres under the Hospital Authority (HA) hospitals were
included in the study. Patients younger than 1 year were
treated under a separate infant ALL study that formed
part of an international multicentre study. The age of
inclusion was thus 1 year to 17.9 years. All the paediatric
ALL patients in Hong Kong were treated in HA hospitals,
this was therefore a population-based study. The
diagnostic criteria were standardised, and morphology and
immunophenotyping were centrally reviewed. Bone
marrow smear was examined after Wright’s stain and
standard cytochemical staining. Acute lymphoblastic
leukaemia was diagnosed in the presence of more than
30% blasts in the bone marrow smear. The French-
American-British morphological classification was not the
essential criteria for diagnosis. Flow cytometry of marrow
aspiration was performed using a batch of monoclonal
antibodies with 20% as the positivity cut-off: CD10, 20, 19,
22 for B lineage, CD3, 5, 7 for T lineage, cytoplasmic and
surface immunoglobulin for pre-B and mature B cell
marker, respectively. The subtype was based on the
scoring system from the EGIL (European Group for the
Immunological Characterization of Acute Leukaemias).
All bone marrow samples were also tested for cytogenetics
by karyotyping, and molecular study for fusion products of
BCR/ABL, TEL/AML1 and MLL/AF4 translocations were
also performed.
The chemotherapy protocol was modified from the
German BFM95 ALL study. The same stratification cri-
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Table 1.  Risk stratification criteria of HKALL97 and HKALL935 studies
HKALL97 (present) study HKALL93 study5
Standard risk Age: 1-5 years Age: 1-9 years
+ WBC* ≤20 x 109 /L + WBC ≤20 x 109 /L
+ Non-T cell + Non-T cell
+ Absence of t(9;22) or t(4;11) + Absence of t(9;22) or t(4;11)
+ Prednisolone good response†
Intermediate risk Age: ≥6 years Age: ≥10 years
or WBC ≥20 x 109 /L or WBC 20-49 x 109 /L
+ Absence of t(9;22) or t(4;11) + Non-T cell
+ Prednisolone good response† + Absence of t(9;22) or t(4;11)
High risk Prednisolone poor response WBC ≥50 x 109 /L
or day 33 non-remission or T-cell
or presence of t(9;22) or t(4;11) or day 29 non-remission
or presence of t(9;22) or t(4;11)
* WBC denotes white blood cell count
† Blast <1.0 x 109 /L in peripheral blood after 7 days of prednisolone pre-phase treatment
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teria were used with the stratification criteria of the HKALL93
study5 shown for comparison (Table 1). A 7-day steroid
pre-phase was included as an important stratification
factor, patients with peripheral blood blast cells of more
than 1.0 x 109 /L on day 8 of steroid treatment would be
included as high risk. The modification included a lower
dose of methotrexate (2 g/m2 instead of 5 g/m2 in the
standard risk), and use of the double re-induction as the
delayed intensification in the high-risk group which was
based on the Italian 95 study.7 The first part of induction
comprised four drugs and lasted 5 weeks. The second part
comprised 4 weeks of cytarabine arabinoside (Ara-C) and 2
doses of high-dose cyclophosphamide. The consolidation
phase included 2 weekly courses of a total of 4 doses of
high-dose methotrexate (2 g/m2 or 5 g/m2 for standard- and
intermediate-risk patients, respectively). The high-risk
treatment included three blocks of very intensive treatment
courses at 3 weekly intervals as consolidation phase.
Each block included 6 days of dexamethasone with a
combination of various high-dose chemotherapeutic
agents (high-dose Ara-C 2 g/m2 every 12 hours intravenous
for 5 doses, high-dose methotrexate 5 g/m2, L-asparaginase
25 000 U/m2, daunorubicin, ifosfamide, etoposide, and
vincristine). The delayed intensification was commenced
at around week 22 after diagnosis, similar to the induc-
tion phase, thus it was also called re-induction. High-
dose dexamethasone was nevertheless used instead of
prednisolone in the first part of re-induction. High-risk
patients received more intensive treatment with double
intensification.7 Prophylactic cranial irradiation at 1200 cGy
for CNS leukaemia was only administered to T-cell and
high-risk patients. Details of the chemotherapy are shown
in Table 2, with HKALL935 chemotherapy shown for
comparison.
Table 2.  Chemotherapy protocol of HKALL97 and HKALL935 studies*
HKALL97 (present) study HKALL93 study5
Induction Week 1-5 Week 1-4
• Prednisolone 60 mg/m2 D1-29 • Prednisolone 40 mg/m2 D1-28
• Vincristine 1.5 mg/m2 D8, 15, 22, 29 • Vincristine 1.5 mg/m2 D1, 8, 15, 22
• L-Asparaginase 5000 IU/m2 IV from D11 Q3D x 8 doses • L-Asparaginase 6000 U/m2 SC from
• Daunorubicin 30 mg/m2 IV weekly D8, 15, 22, 29 • D4 Q3D x 9 doses
• (standard risk: only D8, D15)
Early intensification Week 5-9 Week 6
• Cyclophosphamide 1 g/m2 D36, 64 • Prednisolone 40 mg/m2 D1-5
• Ara-C 75 mg/m2 IV daily on D38-41, 45-48, 52-55, 59-62 • Etoposide 100 mg/m2 IV D1-5
• 6-Mercaptopurine 60 mg/m2 po D36-62 • Daunorubicin 45 mg/m2 IV D1, 2
• Ara-C 100 mg/m2 IV Q12H D1-5
• Thioguanine 80 mg/m2 po D1-5
Consolidation Week 12-20 Week 8-18
Standard risk Standard risk
• Methotrexate 2 g/m2 IV Q2W x 4 • 6-Mercaptopurine intrathecal methotrexate
Intermediate risk Intermediate risk
• Methotrexate 5 g/m2 IV Q2W x 4 • Methotrexate 8 g/m2 or 6 g/m2 IV Q2W x 3
High risk High risk
• Three 6-day intensive blocks including CNS RT 1200 cGy • 6-Mercaptopurine + CNS RT 1800 cGy
Late intensification Week 22-29 (re-induction) Week 20
Standard and intermediate risks All risks
• Dexamethasone 10 mg/m2 po D1-21 • As early intensification
• Vincristine 1.5 mg/m2 IV D8, 15, 22, 29
• L-Asparaginase 10 000 units/m2 IV D11,
• 2 times/week x 4 doses
• Cyclophosphamide 1 g/m2 D36
• Ara-C 75 mg/m2 IV daily on D38-41, 45-48
• 6-Thioguanine 40 mg/m2 po D36-49
High risk High risk: week 35-42
• Repeat late intensification at week 37-44 • Dexamethasone 10 mg/m2 po D1-10
• Vincristine 1.5 mg/m2 IV D1, 8, 15, 22
• L-Asparaginase 6000 unit/m2 IV 3 times/week
• from D4 x 9 doses
• Cyclophosphamide 600 mg/m2 IV D1 of week 39
• and 41
• Ara-C 75 mg/m2 IV D1-4 in week 39-42
• Thioguanine 60 mg/m2 po week 39-42
Maintenance • 6-Mercaptopurine 50 mg/m2 po daily • 6-Mercaptopurine 75 mg/m2 po daily
• Methotrexate 20 mg/m2 po weekly • Methotrexate 20 mg/m2 po weekly
• Dexamethasone 6 mg/m2 po D1-7 and vincristine 1.5 mg/m2 • Prednisolone 40 mg/m2 po D1-5 and vincristine
• IV D1, 8 every 10 week • 1.5 mg/m2 IV D1 every 4 week
• Treatment of up to 2 years from diagnosis • Treatment of up to 2 years from diagnosis
* D denotes day, IV intravenous, Q3D every 3 days, SC subcutaneous, Ara-C cytarabine arabinoside, po orally, Q12H every 12 hours, Q2W every 2 weeks,
CNS RT radiation therapy of the central nervous system
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Statistical analysis
The overall survival and event-free survival (EFS) were
estimated by Kaplan Meier Curve, and the differences in
the risk groups were tested by log-rank test. The HKALL935
and HKALL 97 (present) studies were compared: categori-
cal variables by Chi squared test and continuous variables
by Student’s t test. The survival outcome of the two groups
was compared by log-rank test.
Results
During the 62-month period, 171 patients were recruited,
56.7% of whom were male. The median age at diagnosis
was 5.57 years (range, 1.15-17.85 years). There were three
(1.8%) patients with Down syndrome. The initial median
white blood cell count (WBC) at diagnosis was 12.6 x 109 /L
(range, 0.9-999 x 109 /L). Common ALL was the most
common (56.1%) immunophenotype, and the T cell type
comprised 14.0%. Karyotyping was successful in 141
(82.5%) patients. Among those with successful karyotyping,
chromosome number of higher than 50 (hyperdiploidy)
occurred in 21.3%; both Philadelphia chromosome and
t(1;19) were present in 3.5% of the patients. The risk
stratification according to HKALL97 criteria was standard
risk, 33%; intermediate risk, 55%; and high risk, 11%.
Patient characteristics are shown in Table 3, with the simi-
lar characteristics of HKALL935 patients included for
comparison.
Response to treatment
On day 33 of induction treatment, 163 (95.3%) of 171
patients achieved remission, three patients achieved
remission after further treatment. One of 171 patients
died during induction because of intracranial bleeding and
four did not achieve remission.
At the end of 2004, with a median follow-up period of
48 months (range, 24-86 months from diagnosis), 26
(15.7%) of 166 patients had experienced a relapse, a sig-
nificantly lower proportion than that (37.3%) in the
HKALL93 study5 (P<0.001). Among the relapsers, 13
came from the intermediate-risk group, eight from the
standard-risk group, and five from the high-risk group.
Eleven of 26 relapses occurred within 24 months of
diagnosis, ie before completion of chemotherapy. Of those
patients who relapsed after completion of chemotherapy,
the latest occurred 53 months after diagnosis. The sites of
relapse were bone marrow (n=18), CNS (n=3), combined
bone marrow and CNS (n=2), combined bone marrow and
testes (n=1), testes (n=1), and combined CNS and testes
(n=1). Bone marrow was the main site of relapse in both
studies and was the sole affected site in 60% of relapse cases.
Relapse of CNS, alone or combined with another site,
occurred in six (3.6%) of 166 patients in the HKALL97
study, and 12 (8.2%) of 146 patients in the HKALL93 study.
Allogeneic haematopoietic stem cell transplantation was
performed in 11 patients, four in first remission and seven
in second remission. Five of them survived in remission.
The five patients with Philadelphia chromosome had a poor
outcome: one had refractory leukaemia and died, three
relapsed and two died, and one is in first remission after
transplantation.
Survival outcome according to HKALL97
stratification criteria
Four patients failed to achieve remission after further
chemotherapy and died from infection or bleeding 1.6 to
5.7 months after diagnosis. Four patients died from a non-
leukaemic cause after achieving remission. Three deaths
occurred during the re-induction phase and one following
Table 3.  Patient characteristics
HKALL97 (present) HKALL93 study,5
study, n=171 n=150
Sex
Male 97 (56.7%) 71 (47.3%)
Female 74 (43.3%) 79 (52.7%)
Age (years)
Median 5.57 5.01
Range 1.15-17.85 1.00-15.35
Down syndrome 3 (1.8%) 2 (1.3%)
White blood cell
count (x 109 /L)
Median 12.6 16.9
Range 0.90-999.00 0.40-680.00
Type
Early pre-B 06 (3.5%)0 05 (3.3%)0
Common 96 (56.1%) 96 (64.0%)
Pre-B 38 (22.2%) 33 (22.0%)
T-cell 24 (14.0%) 13 (8.7%)0
Biphenotypic 05 (2.9%)0 01 (0.7%)0
Others 02 (1.2%)0 02 (1.3%)0
Cytogenetics
Successful 141 117
Normal 42 (29.8%) 51 (43.6%)
Hyperdiploidy 30 (21.3%) 24 (20.5%)
t(9;22) 05 (3.5%)0 06 (5.1%)0
t(1;19) 05 (3.5%)0 06 (5.1%)0
Others 59 (41.8%) 30 (25.6%)
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Fig 1. Overall survival of HKALL97 (present) study according
to risk groups
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bone marrow transplantation in the first remission. The
causes of non-leukaemic death were gram-negative bacte-
ria septicaemia and systemic fungal infection. The other
deaths were due to relapsed or refractory leukaemia. At
the last analysis at 2 years after completion of study, 23
patients had died and 148 patients were surviving. The re-
mission status of the survivors was first remission (n=137),
second remission (n=10), and third remission (n=1). The
4-year overall survival for the whole group was 86.5%
(standard deviation [SD], 2.7%). According to the risk
groups, the 4-year overall survival for standard risk, inter-
mediate risk, and high risk were 97.9%, 89.1%, and 58.2%,
respectively (Fig 1). The 4-year EFS for the whole group
was 79% (SD, 3.3%). According to risk groups, the EFS
was 88.5%, 77.9%, and 57.1% for standard risk, intermedi-
ate risk, and high risk, respectively (Fig 2).
Survival outcome according to HKALL93
stratification criteria and comparison of two studies
To enable more accurate comparisons to be made,
HKALL97 patients were reclassified according to
HKALL93 criteria. The HKALL93 study5 adopted less
strict stratification criteria, thus more patients in the
HKALL97 study were classified as standard and high
risks. Comparison of HKALL93 criteria versus HKALL97
criteria for HKALL97 patients revealed there were
47% versus 33% in standard-risk group, 23.5% versus
55% in intermediate-risk group, 29.5% versus 11% in
high-risk group, respectively. There were 24% and 36%
in the HKALL97 intermediate-risk group reclassified as
standard-risk and high-risk respectively according to
HKALL93 criteria. All the HKALL97 standard-
risk patients were also of HKALL93 standard risk,
whereas 16% and 84% of HKALL97 high-risk patients
fell into HKALL93 intermediate-risk and high-risk
groups, respectively. There was no difference in the
overall survival (81.8% for HKALL93 vs 86.5% for
HKALL97, P=0.51) but there was significantly better
EFS for HKALL97 group (65% for HKALL93 vs 79%
for HKALL97, P=0.007) [Fig 3]. According to HKALL93
criteria, the overall survival and EFS for standard risk of
the two studies were not significantly different (P=0.66
and P=0.48). There was a trend of better EFS for HKALL97
study in the intermediate-risk group, 75.6% against 53.1%
for HKALL97 and HKALL93, respectively (P=0.06).
The EFS in high-risk patients of the HKALL97 study
appeared to be better although results did not reach
statistical significance (P=0.14), probably due to the small
sample size.
Discussion
This was a multicentre trial that included all five hospitals
that treat childhood cancer in Hong Kong. It can therefore
be considered a population-based study. All data and events
were recorded prospectively. Randomisation was not
possible because of insufficient patients, thus the findings
of this study were compared with those of a previous one.
The cytogenetic and molecular data were also incomplete.
Nonetheless patient characteristics of the two studies were
similar and both studies were population-based and
included all newly diagnosed ALL children in Hong Kong.
The duration of the two studies was similar—around
5 years—so was the number of patients recruited. Isolation
facilities have improved over the time of these two studies
and Hong Kong now has dedicated children cancer
centre/ward/cubicles in the five public hospitals. Supportive
care is also much improved, with more potent anti-microbials
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and cytokines (eg granulocyte colony-stimulating factor)
available.
The number of non-leukaemia deaths was low in both
studies, 1.3% and 2.3% for HKALL93 and HKALL97,
respectively. Thus the improved outcome currently seen
cannot be explained by a decrease in such deaths, but is
more likely due to the decreased relapse rate (15.7%) in
the HKALL97 study against 37.3% in the HKALL93 study.
This decrease was a result of the increased intensity of
chemotherapy in the HKALL97 study. Number of deaths
due to other causes was not affected.
Overall survival in the HKALL93 and HKALL97 stud-
ies was similar (86.5% vs 81.8%), although the EFS in the
HKALL97 study was superior to that of the HKALL93 study
(79% vs 65%). As in our previous report,5 we observed a
satisfactory overall survival but were dissatisfied with the
poor EFS. The relatively good overall survival was achieved
through further chemotherapy for another 2 to 3 years or
bone marrow transplantation for relapsed patients. In such
patients, we anticipated more late complications such as
growth retardation, endocrine complications, and avascular
necrosis. Secondary brain tumour is the most disastrous
late complication.8 In the new HKALL97 study, the relapse
rate was very much reduced and a second course of treat-
ment was avoided in a large proportion of patients. The re-
duced relapse rate in our study is due to a more effective
chemotherapy protocol. No new chemotherapeutic agents
were administered: the reduced relapse rate was mainly due
to the inclusion of a re-induction phase at around 5 months
after diagnosis. The induction treatment and high-dose
methotrexate during consolidation are quite similar whereas
the early intensification of the HKALL93 study was toxic
with pancytopenia and febrile neutropenia as common
occurrences.5
Re-induction, sometimes called delayed intensification,
is now recognised as an important component of treatment
for ALL in children. The German BFM studies in the 1980s
and 1990s demonstrated improved outcome after introduc-
tion of a more intensive delayed intensification.9 The
American Children’s Cancer Group also demonstrated such
an improvement for both standard- and high-risk patients
after inclusion of the BFM-delayed intensification.10,11 High-
dose dexamethasone may confer better CNS and systemic
anti-leukaemic effects than prednisone.12 Together with
other cytotoxic drugs used in this phase, the minimal
residual leukaemia cells may be further cleared up. In the
current study, we observed better EFS for the whole group,
especially those at intermediate risk. The main difference
in the chemotherapy protocols of the two studies was
the use of dexamethasone and delayed intensification.
Nonetheless this intensive phase is very toxic and associ-
ated with a high infection rate. The three non-leukaemia
deaths in this study all occurred during this delayed
intensification phase, the other patient died following
transplantation.
The present (HKALL97) study included the in-vivo
response to steroid as the stratification criteria. Patients who
exhibited a poor response to 7 days of steroid treatment were
stratified as high risk. This is a simple laboratory test that
can be performed in all laboratories. Its prognostic signifi-
cance has been demonstrated in many studies: it is an in-
dependent predictor for response to treatment and survival
in addition to age and immunophenotyping. White blood
cell count is no longer a distinguishing feature between
intermediate- and high-risk patients. Thus more patients
with high WBC counts were then classified as intermediate
risk. The high-risk group was confined to a small subset of
‘very’ high-risk patients—only 11%. The advantage of fur-
ther defining the high-risk group is the reduced number
of patients subjected to cranial irradiation. The chance of
second malignancy and intellectual impairment is thus
further decreased.13 Whether the reduced dose of cranial
radiotherapy from 1800 cGy to 1200 cGy is less damaging
remains uncertain. The CNS relapse rate remained very low,
1% in standard-risk and 2.2% in intermediate-risk patients,
despite a more restricted cranial irradiation approach.
Despite some modification of this study from the original
BFM95 study, our preliminary results are comparable. The
BFM95 study had 6-year EFS of 79% for the whole group;
and 89%, 79%, and 49% for the standard-, intermediate-,
and high-risk groups, respectively (unpublished data). The
reduction of methotrexate dosage in the current study for
standard-risk patients appeared to be safe.
Conclusion
We observed significant improvement in the survival and
EFS for ALL in Hong Kong children. Cranial irradiation
was avoided in most patients with consequent prevention of
some late complications and improved long-term quality of
life. We are now participating in a multi-national randomised
study aimed at further improving EFS in intermediate-risk
and high-risk patients, and also defining better methods to
improve their quality of life.
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